Compare Crispr Therapeutics AG (CRSP) vs Deutsche Bank AG (DB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Deutsche Bank AG — how do they compare? Crispr Therapeutics AG trades at $53.42 (market cap $4.88B), while Deutsche Bank AG trades at $33.69 (market cap $62.42B). The key difference: Deutsche Bank AG is far larger — about 12.8× Crispr Therapeutics AG's market cap, and Deutsche Bank AG pays a 3.46% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Deutsche Bank AG for 80 Days on average.
| CRSP | DB | |
|---|---|---|
Market Cap | $4.88B | $62.42B |
Volume | 2,861,747 | 2,918,760 |
Sector | Health | Financials |
52-Week High | $74.92 | $41.56 |
52-Week Low | $44.34 | $28.37 |
Typical Hold Time | 77 Days | 80 Days |
Enterprise Value | $3.30B | $77.06B |
Dividend Yield | — | 3.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
Deutsche Bank (DB) trades at $33.68, up 0.39% today, with a bearish technical signal from moving averages but recent earnings beats. The stock shows attractive valuation with a P/E of 9.09 and P/B of 0.71, while net income surged to $6.93B in 2025. News highlights include strategic appointments and a raised 2026 net interest income outlook, though Q3 investment banking revenue is expected to be flat to slightly down.
The outlook is mixed: strong fundamentals and cost-saving initiatives support growth toward 2028 targets, but bearish technicals and a high proportion of hold ratings suggest near-term caution. Key risks include volatile investment banking revenue and macroeconomic pressures, while institutional sentiment remains divided with 57.58% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
